Base editors
| CRISPR Medicine | This is an overview of articles on base editors
Sign-up to weekly Newsletter here.
Base editors
| CRISPR Medicine | This is an overview of articles on base editors
Sign-up to weekly Newsletter here.
IND Enabling
Phase I
Phase II
Phase III
Gastric Cancer and Colorectal Cancer, CRC, (NCT07166263)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541444)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Pediatric Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541405)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Refractory Systemic Lupus Erythematosus, SLE, (NCT07083349)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III